Hypertension Drugs Market 2016-2020

Table of Contents

PART 01: Executive summary

• Highlights

PART 02: Scope of  the report

• Market overview
• Top-vendor offerings

PART 03: Market research methodology

• Research methodology
• Economic indicators

PART 04: Introduction

• Key market highlights
• Key buying criteria

PART 05: Cardiovascular drugs market

• Global pharmaceuticals market
• Global cardiovascular drugs market

PART 06: Overview: Hypertension

• Systemic hypertension
• PAH

PART 07: Epidemiology and economic burden

• Economic burden

PART 08: Pipeline portfolio

PART 09: Market landscape

• Market overview
• Market size and forecast
• Five forces analysis

PART 10: Market segmentation by type

• Global systemic hypertension drugs market
• Global PAH drugs market

PART 11: Market segmentation by drug class

• Systemic hypertension
• PAH

PART 12: Geographical segmentation

• Global hypertension drugs market by geographical segmentation 2015-2020
• Hypertension drugs market in Americas
• Hypertension drugs market in EMEA
• Hypertension drugs market in APAC

PART 13: Market drivers

• Growing older population
• Rise in sedentary lifestyle
• High prevalence of chronic conditions
• Patient assistance programs

PART 14: Impact of drivers

PART 15: Market challenges

• Patent expiries of major drugs
• Adverse effects
• Poor patient compliance
• Availability of alternative therapies

PART 16: Impact of drivers and challenges

PART 17: Market trends

• Increase in awareness
• Increased focus on combination therapies
• Intense competition among vendors
• Strategic alliances

PART 18: Vendor landscape

• Competitive scenario
• Market share 2015
• Novartis
• Daiichi Sankyo
• Actelion Pharmaceuticals
• Boehringer Ingelheim
• Sanofi
• AstraZeneca
• Other prominent vendors

PART 19: Appendix

• List of abbreviations

PART 20: Explore Technavio